版本:
中国

BRIEF-Prometic's PBI-4050 significantly reduces liver fibrosis in patients with alström syndrome

Oct 12 Prometic Life Sciences Inc :

* Prometic's PBI-4050 significantly reduces liver fibrosis in patients with alström syndrome

* Prometic Life Sciences-significant reduction of established liver fibrosis demonstrated in all patients that completed 12 weeks of PBI-4050 treatment

* Prometic Life Sciences Inc - liver enzymes reduced to within normal ranges in all patients that completed 12 weeks of PBI-4050 treatment

* Prometic Life Sciences Inc - alström syndrome clinical program to be expanded to include further sites throughout europe and north america

* Prometic Life Sciences-drug safety monitoring board recommended patient enrolment should continue in co's ongoing alström syndrome phase 2 clinical trial Source text for Eikon: Further company coverage:

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐